{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Danaher Corp. technically bullish or bearish?
As of October 31, 2025, Danaher Corp. shows a mildly bullish trend with mixed technical signals, including a bullish weekly MACD and bearish monthly MACD, while underperforming the S&P 500 year-to-date and over the past year.
Is Danaher Corp. technically bullish or bearish?
As of October 31, 2025, Danaher Corp. shows a mildly bullish trend driven by weekly bullish indicators, despite mixed signals from monthly metrics and underperformance compared to the S&P 500.
Is Danaher Corp. technically bullish or bearish?
As of October 31, 2025, Danaher Corp. shows a mildly bullish technical trend despite underperforming the S&P 500, with mixed signals from MACD and moving averages across different time frames.
Danaher Corp. Faces Valuation Shift Amid Declining Financial Performance and Profit Challenges
Danaher Corp., a key player in the Pharmaceuticals & Biotechnology sector, has undergone a valuation grade adjustment, now classified as very expensive. Key financial metrics include a P/E ratio of 40 and a Price to Book Value of 3.30, amid challenges like declining profits and flat financial performance.
Is Danaher Corp. overvalued or undervalued?
As of October 17, 2025, Danaher Corp. is considered very expensive with a P/E ratio of 40 and has underperformed the S&P 500, showing a year-to-date return of -8.93% compared to the index's 13.30%.
Danaher Corp. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape
Danaher Corp., a key player in the Pharmaceuticals and Biotechnology sector, has a high P/E ratio of 40, indicating a strong market position. Despite recent outperformance over the S&P 500, the company has faced declines year-to-date and over the past year, contrasting with gains in the broader index.
Is Danaher Corp. overvalued or undervalued?
As of October 17, 2025, Danaher Corp. is considered very expensive and overvalued with a P/E ratio of 40, significantly higher than peers like Abbott Laboratories and Thermo Fisher Scientific, and has underperformed the S&P 500 across various timeframes.
Danaher Corp. Experiences Evaluation Revision Amidst Market Challenges and Performance Indicators
Danaher Corp., a key player in the Pharmaceuticals & Biotechnology sector, has recently seen its stock price decline. Over the past year, the company has struggled, significantly underperforming compared to the S&P 500. Technical indicators show mixed signals, reflecting ongoing challenges in the competitive market.
Is Danaher Corp. technically bullish or bearish?
As of October 3, 2025, Danaher Corp. shows a mildly bearish trend with mixed indicators, having outperformed the S&P 500 recently but underperformed over the past year.
Is Danaher Corp. technically bullish or bearish?
As of October 3, 2025, Danaher Corp. is in a mildly bearish trend, with mixed indicators showing short-term outperformance against the S&P 500 but significant underperformance year-to-date.
Danaher Corp. Hits Day High with Strong 9.26% Intraday Surge
Danaher Corp., a key player in the Pharmaceuticals & Biotechnology sector, saw a notable increase in its stock today, reaching an intraday high. Despite this surge, the company has faced mixed performance trends, with declines over the past month, year-to-date, and longer-term periods, reflecting ongoing financial complexities.
Is Danaher Corp. technically bullish or bearish?
As of July 24, 2025, Danaher Corp. is in a mildly bearish trend, with mixed signals from MACD and Bollinger Bands, and has underperformed the S&P 500 with year-to-date and one-year returns of -14.93% and -28.18%, respectively.
Is Danaher Corp. overvalued or undervalued?
As of August 5, 2025, Danaher Corp. is considered very expensive and overvalued with high valuation ratios and significant underperformance compared to the S&P 500.
Is Danaher Corp. technically bullish or bearish?
As of June 3, 2025, Danaher Corp. exhibits a mildly bearish technical trend, influenced by mixed signals from MACD, moving averages, Bollinger Bands, and Dow Theory indicators.
Is Danaher Corp. overvalued or undervalued?
As of April 25, 2025, Danaher Corp. is considered overvalued with a valuation grade of expensive, reflected by a P/E ratio of 40 and a decline of 22.99% in stock performance over the past year, while its return on equity of 8.34% suggests insufficient profitability to support its high valuation compared to peers like Abbott Laboratories and Thermo Fisher Scientific.
Who are in the management team of Danaher Corp.?
As of March 2022, the management team of Danaher Corp. includes Steven Rales (Chairman), Rainer Blair (CEO), Linda Hefner Filler (Lead Independent Director), Mitchell Rales, Teri List-Stoll, Walter Lohr, and Jessica Mega (all Independent Directors).
What does Danaher Corp. do?
Danaher Corporation designs and manufactures products and services in the Pharmaceuticals & Biotechnology industry, with recent net sales of $5.74 billion and a market cap of approximately $167.63 billion. Key metrics include a P/E ratio of 40.00 and a dividend yield of 0.49%.
How big is Danaher Corp.?
As of Jun 18, Danaher Corp. has a market capitalization of $167.63 billion, with recent net sales of $23.82 billion and a net profit of $3.77 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
